Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.57 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10461990 | 0.92 | NPC1 (0.71) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL14113144 | 0.84 | NPC1 (0.93) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL5145130 | 0.83 | NPC1 (0.69) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL9123987 | 0.83 | NPC1 (0.69) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL92225 | 0.83 | NPC1 (0.69) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL9732793 | 0.83 | NPC1 (0.73) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL9732903 | 0.81 | NPC1 (0.71) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL9389817 | 0.81 | NPC1 (0.67) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL8795293 | 0.81 | NPC1 (0.71) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL10425925 | 0.81 | NPC1 (0.66) | NPC1RAB9AHPGDSMN1; SMN2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0775689-B9 | NOVEL AMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF AS ANTIARRHYTHMIC | C & C RES LABS (KR) | 2004-09-15 | — | — | EP | disclosed |
| EP-0775689-B1 | NOVEL AMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF AS ANTIARRHYTHMIC | C & C RES LABS (KR) | 2003-09-03 | — | — | EP | disclosed |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| EP-0824098-B1 | 4-hydroxy-piperidine derivatives | HOFFMANN LA ROCHE (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1086063-A4 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1086063-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6057358-A | POTASSIUM CHANNEL BLOCKING ANTIARRHYTHMIC DRUGS WITH LESS SIDE EFFECTS | C&C RESEARCH LABS. (KR) | 2000-05-02 | — | — | US | disclosed |
| WO-1999064050-A9 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5889026-A | 4-hydroxy-piperodine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0431943-B1 | Spiro(pyran)piperidine derivatives | MERCK & CO INC (US) | 1998-07-15 | — | — | EP | disclosed |
| EP-0824098-A1 | 4-hydroxy-piperidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-18 | — | — | EP | disclosed |
| EP-0775689-A1 | NOVEL AMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF AS ANTIARRHYTHMIC | C & C RESEARCH LABS. (KR) | 1997-05-28 | — | — | EP | disclosed |
| US-5633247-A | ANTIARRTHYMIA AGENT | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0431943-A2 | Nitrogen-containing spirocycles | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | NPC1 220/4885RAB9A 1595/4885HPGD 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.